11th Annual Forum for Qualified Persons in Pharmacovigilance

This is the only forum designed for QPPVs by QPPVs, now in its 11th year and ever growing. This year’s objectives build on past successes and have been shaped by valuable feedback provided by participants.

Back to Agenda

Session 4: Brexit - the impact on pharmacogivilance activities

Session Chair(s)

Peter De Veene, MD

GQPPV

MSD Belgium, Belgium

On 29 March 2017, the United Kingdom (UK) notified the European Council of its intention to withdraw from the European Union (EU), a process known as 'Brexit'. In this session, we will explore the implications of this Brexit on the pharmaceutical industry and in particular the consequences for the pharmacovigilance area, both in terms of regulatory system as well as the impact on companies. We will hear both from the regulators and industry how these changes might impact us and how we can prepare to minimize the impact after the UK leaves the EU on 30 March 2019. There will be a Q&A session to follow.

Speaker(s)

Q&A

Vicki Edwards, RPh

Abbvie, United Kingdom

Vice President, Pharmacovigilance Excellence and International QPPV

The future of Pharmacovigilance systems in UK after Brexit

Mick Foy

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Director of Delivery

Agnès Saint-Raymond, DrMed

European Medicines Agency, Netherlands

Head of Division International Affairs

Have an account?